---
title: "ZHIFEI-BIOL: The company's self-developed influenza virus split vaccine has obtained a drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259325738.md"
description: "ZHIFEI-BIOL's wholly-owned subsidiary ZHIFEI Longke Ma has developed a split influenza virus vaccine that has received the drug registration certificate from the National Medical Products Administration. This vaccine is suitable for individuals aged 32 and above and is used to prevent infectious diseases caused by the influenza virus. It is one of the main products for influenza prevention both domestically and internationally. The registered trivalent influenza vaccine, along with the quadrivalent influenza vaccine already approved by the company and other products under research, forms a rich series of influenza vaccines"
datetime: "2025-09-29T11:36:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259325738.md)
  - [en](https://longbridge.com/en/news/259325738.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259325738.md)
---

# ZHIFEI-BIOL: The company's self-developed influenza virus split vaccine has obtained a drug registration certificate

ZHIFEI-BIOL announced that its wholly-owned subsidiary ZHIFEI-Longke has developed an influenza virus split vaccine that has received the "Drug Registration Certificate" issued by the National Medical Products Administration. This vaccine is suitable for individuals aged 32 and above to prevent infectious diseases caused by influenza virus and is currently one of the main products for influenza prevention both domestically and internationally. The trivalent influenza vaccine that has obtained the drug registration certificate, along with the quadrivalent influenza virus split vaccine that has been approved for market launch, the quadrivalent/trivalent influenza virus split vaccine that is under review for market launch, the quadrivalent influenza virus split vaccine that is in Phase I/II clinical trials, and the trivalent influenza virus split vaccine that has been approved for clinical use, constitutes a comprehensive series of influenza vaccine products covering all age groups and with a rich variety

### Related Stocks

- [300122.CN](https://longbridge.com/en/quote/300122.CN.md)

## Related News & Research

- [Obamacare Meltdown? Sharp ACA Enrollment Drop Expected As Pandemic-Era Subsidies End](https://longbridge.com/en/news/287067300.md)
- [Farnam Celebrates 80 Years of Horse Care With New Innovations and the Horse Care Grant Sweepstakes | CENT Stock News](https://longbridge.com/en/news/287053110.md)
- [Figure AI had one of its robots race a human to sort packages. It lost.](https://longbridge.com/en/news/286883540.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)
- [DJI’s e-bike division tries to defend why its motors are so insanely powerful](https://longbridge.com/en/news/286894898.md)